These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

893 related items for PubMed ID: 31492652

  • 21. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [Abstract] [Full Text] [Related]

  • 22. Alemtuzumab for multiple sclerosis.
    Riera R, Porfírio GJ, Torloni MR.
    Cochrane Database Syst Rev; 2016 Apr 15; 4(4):CD011203. PubMed ID: 27082500
    [Abstract] [Full Text] [Related]

  • 23. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
    Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB, SIMCOMBIN study investigators.
    Lancet Neurol; 2011 Aug 15; 10(8):691-701. PubMed ID: 21742556
    [Abstract] [Full Text] [Related]

  • 24. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators.
    Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652
    [Abstract] [Full Text] [Related]

  • 25. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II investigators.
    Lancet; 2012 Nov 24; 380(9856):1829-39. PubMed ID: 23122650
    [Abstract] [Full Text] [Related]

  • 26. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
    Mult Scler Relat Disord; 2021 Jun 24; 51():102844. PubMed ID: 33892317
    [Abstract] [Full Text] [Related]

  • 27. Fingolimod for relapsing-remitting multiple sclerosis.
    La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G.
    Cochrane Database Syst Rev; 2016 Apr 19; 4(4):CD009371. PubMed ID: 27091121
    [Abstract] [Full Text] [Related]

  • 28. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 19; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 29. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
    Zhang J, Shi S, Zhang Y, Luo J, Xiao Y, Meng L, Yang X.
    Cochrane Database Syst Rev; 2017 Nov 27; 11(11):CD010968. PubMed ID: 29178444
    [Abstract] [Full Text] [Related]

  • 30. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L, INFORMS study investigators.
    Lancet; 2016 Mar 12; 387(10023):1075-1084. PubMed ID: 26827074
    [Abstract] [Full Text] [Related]

  • 31. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA.
    Mult Scler; 2022 Oct 12; 28(12):1944-1962. PubMed ID: 35765217
    [Abstract] [Full Text] [Related]

  • 32. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 33. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA, Ozanimod Study Investigators.
    Eur J Neurol; 2021 Nov 25; 28(11):3722-3730. PubMed ID: 34292643
    [Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
    Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T.
    Lancet Neurol; 2016 Oct 25; 15(11):1148-59. PubMed ID: 27543447
    [Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
    Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI, SYNERGY study investigators.
    Lancet Neurol; 2019 Sep 25; 18(9):845-856. PubMed ID: 31285147
    [Abstract] [Full Text] [Related]

  • 36. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul 25; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 37. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun 25; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

  • 38. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
    Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E.
    Lancet Neurol; 2013 Aug 25; 12(8):756-67. PubMed ID: 23764350
    [Abstract] [Full Text] [Related]

  • 39. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Aug 25; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 25; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.